Funded in part by AstraZeneca, Gedeon Richter, Novo Nordisk, Vifor Pharma
The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD)
Bressendorff I, Hansen D, Schou M, Kragelund C, Svensson M, Hashemi B, Kristensen T, Vrist MH, Borg R, Tougaard B, Borg K, Hjortkjær HØ, Kristiansen CH, Carlson N, Nasiri M, Ashraf H, Pasch A, Brandi L
Journal of the American Society of Nephrology : JASN · 39 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- AstraZeneca
- Company
- Gedeon Richter
- Company
- Novo Nordisk
- Nonprofit
- Dansk Nefrologisk Selskab
- Company
- Vifor Pharma
Based on 5 listed funder(s).
Publication
- Published
- 2023-02-02 · J Am Soc Nephrol · vol. 34 · issue 5 · pp. 886–894
- Publisher
- American Society of Nephrology
- Cited
- 54 citations · more than 98% of similar papers · 6.5× the field average
- Impact
- Top 10% most cited in its field
- References
- 18 works
- Access
- Open access (journal) · OTHER-OA
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Keywords
- Medicine, Randomized controlled trial, Magnesium, Internal medicine, Kidney disease, Calcification, Chemistry
- MeSH
- humans, magnesium, dietary supplements, renal insufficiency, chronic, coronary artery disease, vascular calcification
18 authors
From DK, NO, AT
- Iain Oshoj Bressendorff · correspondingGentofte Hospital; Nordsjællands Hospital
- Ditte HansenAalborg University Hospital; Odense University Hospital; Aarhus University Hospital; Gentofte Hospital; Rigshospitalet; Zealand University Hospital
- Morten SchouAalborg University Hospital; Odense University Hospital; Aarhus University Hospital; Gentofte Hospital; Rigshospitalet; Zealand University Hospital
- Charlotte KragelundAalborg University Hospital; Odense University Hospital; Aarhus University Hospital; Gentofte Hospital; Rigshospitalet; Zealand University Hospital; Nordsjællands Hospital
- My Hanna Sofia SvenssonAkershus University Hospital
- Bahram HashemiAalborg University Hospital; Odense University Hospital; Aarhus University Hospital; Gentofte Hospital; Rigshospitalet; Zealand University Hospital
Abstract
Significance statement
Magnesium prevents vascular calcification in animals with CKD. In addition, lower serum magnesium is associated with higher risk of cardiovascular events in CKD. In a randomized, double-blinded, placebo-controlled trial, the authors investigated the effects of magnesium supplementation versus placebo on vascular calcification in patients with predialysis CKD. Despite significant increases in plasma magnesium among study participants who received magnesium compared with those who received placebo, magnesium supplementation did not slow the progression of vascular calcification in study participants. In addition, the findings showed a higher incidence of serious adverse events in the group treated with magnesium. Magnesium supplementation alone was not sufficient to delay progression of vascular calcification, and other therapeutic strategies might be necessary to reduce the risk of cardiovascular disease in CKD.
Background
Elevated levels of serum magnesium are associated with lower risk of cardiovascular events in patients with CKD. Magnesium also prevents vascular calcification in animal models of CKD.
Methods
To investigate whether oral magnesium supplementation would slow the progression of vascular calcification in CKD, we conducted a randomized, double-blinded, placebo-controlled, parallel-group, clinical trial. We enrolled 148 subjects with an eGFR between 15 and 45 ml/min and randomly assigned them to receive oral magnesium hydroxide 15 mmol twice daily or matching placebo for 12 months. The primary end point was the between-groups difference in coronary artery calcification (CAC) score after 12 months adjusted for baseline CAC score, age, and diabetes mellitus.
Results
A total of 75 subjects received magnesium and 73 received placebo. Median eGFR was 25 ml/min at baseline, and median baseline CAC scores were 413 and 274 in the magnesium and placebo groups, respectively. Despite plasma magnesium increasing significantly during the trial in the magnesium group, the baseline-adjusted CAC scores did not differ significantly between the two groups after 12 months. Prespecified subgroup analyses according to CAC>0 at baseline, diabetes mellitus, or tertiles of serum calcification propensity did not significantly alter the main results. Among subjects who experienced gastrointestinal adverse effects, 35 were in the group receiving magnesium treatment versus nine in the placebo group. Five deaths and six cardiovascular events occurred in the magnesium group compared with two deaths and no cardiovascular events in the placebo group.
Conclusions
Magnesium supplementation for 12 months did not slow the progression of vascular calcification in CKD, despite a significant increase in plasma magnesium.
Clinical trials registration
www.clinicaltrials.gov ( NCT02542319 ).
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.